Nexalin Technology, Inc. NXL
Institutional shares held
1.37 Million
0
calls
0
puts
Total value of holdings
$1.16M
$0
calls
$0
puts
Market Cap
$6.19M
7,279,960
Shares Out.
Institutional ownership
18.81%
# of Institutions
22
We take great care to ensure that the data presented and summarized in this overview for Nexalin Technology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NXL
View all-
Myda Advisors LLC Inwood, NY800KShares$680,0000.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA160KShares$135,8960.0% of portfolio
-
Geode Capital Management, LLC Boston, MA116KShares$98,9110.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE55.5KShares$47,1420.81% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny46.3KShares$39,3920.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il37.3KShares$31,6950.0% of portfolio
-
State Street Corp Boston, MA32.3KShares$27,4550.0% of portfolio
-
Northern Trust Corp Chicago, IL24.1KShares$20,4850.0% of portfolio
-
Xtx Topco LTD London, X022.1KShares$18,8220.0% of portfolio
-
Ubs Group Ag15.1KShares$12,8220.0% of portfolio
Latest Institutional Activity in NXL
Top Purchases
Top Sells
About NXL
Insider Transactions at NXL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2025
|
Carolyn Hamby Shelton Sr. VP - Quality, Regulatory |
BUY
Open market or private purchase
|
Indirect |
6,000
+16.67%
|
$12,000
$2.2 P/Share
|
|
Feb 04
2025
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.64%
|
$6,000
$3.04 P/Share
|
|
Jan 28
2025
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+0.97%
|
$3,000
$2.7 P/Share
|
|
Jan 23
2025
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.65%
|
$2,000
$2.7 P/Share
|
|
Jan 13
2025
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+1.3%
|
$4,000
$2.5 P/Share
|
|
Oct 28
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
500
+0.34%
|
$1,000
$2.19 P/Share
|
|
Sep 30
2024
|
Ben Hu Director |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+33.94%
|
-
|
|
Sep 30
2024
|
Leslie Bernhard Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,838
+50.0%
|
-
|
|
Sep 23
2024
|
Marilyn Elson > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
700,000
+31.32%
|
-
|
|
Aug 13
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.67%
|
$0
$0.95 P/Share
|
|
Jun 28
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.68%
|
$1,000
$1.75 P/Share
|
|
Jun 18
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,619
+1.1%
|
$0
$0.71 P/Share
|
|
Jun 10
2024
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+1.03%
|
$0
$0.64 P/Share
|
|
Sep 28
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,500
+1.12%
|
$9,500
$1.12 P/Share
|
|
Sep 16
2022
|
David Owens Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.74%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Mark White President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.86%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Rick Morad Director |
BUY
Open market or private purchase
|
Direct |
2,500
+2.26%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Alan Kazden Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+2.73%
|
$10,000
$4.15 P/Share
|
|
Sep 16
2022
|
Marilyn Elson > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,000
+4.18%
|
$144,000
$4.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
938K
Shares
From
5
Insiders
| Grant, award, or other acquisition | 925K shares |
|---|---|
| Open market or private purchase | 13K shares |
Sell / Disposition
0
Shares
From
0
Insiders